ASCO 2024 - LBA4: The ADRIATIC Study
LBA5 (Spigel): Durvalumab ± tremelimumab as consolidation therapy for patients with limited- stage small-cell lung cancer (LS-SCLC): Results from the phase 3 ADRIATIC study.
LBA5 (Spigel): Durvalumab ± tremelimumab as consolidation therapy for patients with limited- stage small-cell lung cancer (LS-SCLC): Results from the phase 3 ADRIATIC study.
Пікірлер